PERFORMANCE RIGHTS APPROVED BY SHAREHOLDERS

Lynas Corporation Ltd (ASX:LYC, OTC:LYSDY) confirms that, during the AGM held on 28 November 2017, Shareholders approved Resolution 6 relating to a proposed award of Performance Rights. As set out in the Company’s announcement dated 26 September 2017 and in the 2017 AGM Notice, the Performance Rights that are now being awarded in accordance with Resolution 6 are as follows:

1. 2,123,905 FY17 STI performance rights for the benefit of Amanda Lacaze, the Lynas CEO and Managing Director. This award of STI Performance Rights arose from satisfaction of performance hurdles relating to FY17. The performance hurdles that were satisfied in FY17 related to cash balances, NdPr production volume, cost targets and team / individual performance. The STI Performance Rights have a 1 year vesting period. Further detail is provided in the remuneration report section of the FY17 financial report and in the 2017 AGM Notice.

2. 8,091,065 Strategic Performance Rights for the benefit of Amanda Lacaze and 21,238,108 Strategic Performance Rights for the benefit of other members of the senior leadership team. The Strategic Performance Rights have a 2 year vesting period and they are subject to the following vesting conditions:

   (a) the recipient remaining employed by Lynas for at least the next 2 years and performing at an acceptable level; and

   (b) delivering the Lynas NEXT targets on time and on budget, including 600 tonnes of NdPr per month.

   Further details are provided in the Company’s announcement dated 26 September 2017, the 2017 AGM Notice and the 2017 AGM Presentation.

3. 4,236,201 LTI Performance Rights for the benefit of Amanda Lacaze. The LTI Performance Rights have a three year vesting period and they are subject to vesting conditions relating to EBITDA growth and Total Shareholder Return over the next three years. Further details are provided in the Company’s announcement dated 26 September 2017 and in the 2017 AGM Notice.

Attached is an Appendix 3B concerning the award of Performance Rights.

For all media enquiries please contact Renee Bertuch from Cannings Corporate Communications on +61 2 8284 9990.

Andrew Arnold
Company Secretary
Name of entity

<table>
<thead>
<tr>
<th>LYNAS CORPORATION LTD</th>
</tr>
</thead>
</table>

ABN

| 27 009 066 648 |

We (the entity) give ASX the following information.

**Part 1 - All issues**

You must complete the relevant sections (attach sheets if there is not enough space).

1. **Class of securities issued or to be issued**: Unlisted Performance Rights

2. **Number of securities issued or to be issued (if known) or maximum number which may be issued**: 35,689,279 Performance Rights

3. **Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)**: The Employee Performance Rights are subject to the Performance Conditions specified in the attached Announcement and are exercisable without further consideration on the dates specified in section 9.
4. Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

| N/A |

5. Issue price or consideration

The Performance Rights were valued at $0.1558 per Performance Right

6. Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

To be granted for the benefit of selected senior employees as incentive rewards.

6a. Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

| No |

6b. The date the security holder resolution under rule 7.1A was passed

6c. Number of *securities issued without security holder approval under rule 7.1

6d. Number of *securities issued with security holder approval under rule 7.1A

+ See chapter 19 for defined terms.
6e  Number of securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

6f  Number of securities issued under an exception in rule 7.2

6g  If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

6h  If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i  Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7  Dates of entering +securities into uncertificated holdings or despatch of certificates

The Performance Rights will be granted with effect from the date of Board approval of the proposed grant of Performance Rights, being 28 August 2017

8  Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>+Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>5,486,809,034</td>
<td>Ordinary shares</td>
</tr>
<tr>
<td>Number</td>
<td>Class</td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>3,537,736</td>
<td>Class 2 Employee Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 23 September 2017 to 23 September 2019</td>
</tr>
<tr>
<td>2,830,189</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 23 September 2017 to 23 September 2019</td>
</tr>
<tr>
<td>44,888,179</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 18 September 2018 to 18 September 2020</td>
</tr>
<tr>
<td>10,054,019</td>
<td>STI Performance Rights exercisable for no further consideration in the first employee trading window after 30 August 2017</td>
</tr>
<tr>
<td>22,185,717</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 30 August 2019 to 30 August 2021</td>
</tr>
<tr>
<td>7,462,781</td>
<td>STI Performance Rights exercisable for no further consideration in the first employee trading window after 28 August 2018</td>
</tr>
<tr>
<td>29,329,173</td>
<td>Strategic Performance Rights exercisable for no further consideration, subject to vesting conditions, in the first employee trading window after 28 August 2019</td>
</tr>
<tr>
<td>9,003,311</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 28 August 2020 to 28 August 2022</td>
</tr>
<tr>
<td>96,500,000</td>
<td>US$96,500,000 of Convertible Bonds at 1.875% p.a. maturing 30 September 2020, convertible at A$0.10 per share based on an exchange rate of A$1.00 = US$0.75</td>
</tr>
<tr>
<td>271,322,983</td>
<td>Warrants exercisable at $0.05 on or before 30 September 2020</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)</td>
</tr>
</tbody>
</table>

**Part 2 - Bonus issue or pro rata issue**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Is security holder approval required?</td>
</tr>
<tr>
<td>12</td>
<td>Is the issue renounceable or non-renounceable?</td>
</tr>
<tr>
<td>13</td>
<td>Ratio in which the *securities will be offered</td>
</tr>
<tr>
<td>14</td>
<td>*Class of *securities to which the offer relates</td>
</tr>
<tr>
<td>15</td>
<td>*Record date to determine entitlements</td>
</tr>
<tr>
<td>16</td>
<td>Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</td>
</tr>
<tr>
<td>17</td>
<td>Policy for deciding entitlements in relation to fractions</td>
</tr>
<tr>
<td>18</td>
<td>Names of countries in which the entity has *security holders who will not be sent new issue documents</td>
</tr>
</tbody>
</table>

*Note: Security holders must be told how their entitlements are to be dealt with.*

*Cross reference: rule 7.7.*

| 19 | Closing date for receipt of acceptances or renunciations |   |
| 20 | Names of any underwriters |   |
| 21 | Amount of any underwriting fee or commission |   |
22 Names of any brokers to the issue

23 Fee or commission payable to the broker to the issue

24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of "security holders"

25 If the issue is contingent on "security holders' approval, the date of the meeting

26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled

27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

28 Date rights trading will begin (if applicable)

29 Date rights trading will end (if applicable)

30 How do "security holders sell their entitlements in full through a broker?"

31 How do "security holders sell part of their entitlements through a broker and accept for the balance?"

32 How do "security holders dispose of their entitlements (except by sale through a broker)?"

33 "Despatch date"

+ See chapter 19 for defined terms.
Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34  Type of securities
     (tick one)

(a) [ ] Securities described in Part 1

(b) [ ] All other securities
     Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35  [ ] If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  [ ] If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
     1 - 1,000
     1,001 - 5,000
     5,001 - 10,000
     10,001 - 100,000
     100,001 and over

37  [ ] A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38  Number of securities for which +quotation is sought

39  Class of +securities for which quotation is sought
40. Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41. Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

42. Number and class of all securities quoted on ASX (including the securities in clause 38)

<table>
<thead>
<tr>
<th>Number</th>
<th>*Class</th>
</tr>
</thead>
</table>

+ See chapter 19 for defined terms.
Quotation agreement

1 Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.

2 We warrant the following to ASX.
   - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
   - There is no reason why those *securities should not be granted *quotation.
   - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
     Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
   - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
   - If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ___________________________ Date: 29 November 2017

Company Secretary)

Print name: ANDREW ARNOLD

+ See chapter 19 for defined terms.